With great interest, we read the report of Lu et al on the influence of proton pomp inhibitor (PPI) therapy on the outcome of infliximab therapy in inflammatory bowel disease (IBD).1 The authors analysed patient-level data from five randomised controlled trials (RCTs) of patients with IBD treated with infliximab. A total of 1036 patients were enrolled, of whom 147 on PPI therapy. They found that patients on PPI were less likely to achieve remission compared with patients not taking PPIs (OR 0.45, p<0.001) and conclude that PPIs negatively affects outcome in patients with IBD treated with infliximab and PPIs should be prescribed with caution. We like to congratulate the authors to study the effect of frequently prescribed drugs on the outcome of anti-tumor necrosis factor therapy, since the knowledge on drug–drug interactions is scarce and based on observational …

中文翻译：

---

IBD 患者的 PPI 和抗 TNF：禁用组合？

我们怀着极大的兴趣阅读了 Lu 等人关于质子泵抑制剂 (PPI) 治疗对英夫利昔单抗治疗炎症性肠病 (IBD) 结果影响的报告。1 作者分析了来自五项随机对照试验的患者水平数据(RCTs) 的 IBD 患者接受英夫利昔单抗治疗。共招募了 1036 名患者，其中 147 名接受 PPI 治疗。他们发现，与不服用 PPI 的患者相比，服用 PPI 的患者获得缓解的可能性更小（OR 0.45，p<0.001），并得出结论，PPI 对接受英夫利昔单抗治疗的 IBD 患者的预后有负面影响，应谨慎使用 PPI。我们要祝贺作者研究常用处方药对抗肿瘤坏死因子治疗结果的影响，